Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review
Besag FMC, Vasey MJ, Lao KSJ, Wong ICK
Published in CNS Drugs
Methodology
Systematic review of randomised and observational studies reporting adverse events with melatonin used for primary or secondary sleep disorders in children and adults.
Key Findings
Reported adverse events were generally mild and comparable to placebo, most commonly daytime sleepiness, headache, dizziness and nausea; no consistent evidence of serious harm emerged, but long-term data remain sparse.
Conclusions
Melatonin has a favourable short-term safety profile, with uncertainty about prolonged use.
Limitations
Inconsistent adverse event reporting across studies; few trials longer than three months.
Supplements Studied
Reported adverse events were generally mild and comparable to placebo, most commonly daytime sleepiness, headache, dizziness and nausea.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.